Have you been diagnosed with low-grade serous ovarian cancer (LGSOC)?

If so, Verastem Oncology is sponsoring the RAMP 201 (Raf And Mek Program) Phase 2 clinical trial that might be right for you.

Take the pre-screener
verastem logo

Trial Overview

Study Overview:
The purpose of the RAMP 201 study, also referred to as a trial, is to see whether an investigational drug called VS-6766 given to patients with recurrent LGSOC with and without a KRAS mutation works better alone or when given in combination with a second investigational drug, defactinib. The trial will measure effectiveness, including overall response rate, as well as safety. The study is being conducted by gynecological cancer specialists.

If you are eligible and agree to participate in this study, you will be treated with either VS-6766 alone or a combination of VS-6766 with defactinib, for up to one year with follow up appointments. This is an open-label trial. Every patient will be treated with an active oral study drug, and their investigator will not be comparing it to a placebo.

VS-6766 and defactinib are investigational compounds that have not been approved by the U.S. Food and Drug Administration (FDA). Defactinib was granted Orphan Drug Designation in ovarian cancer and mesothelioma in the U.S., EU and Australia.

Protocol Title:
RAMP 201: A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination with Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Protocol Numbers:
VS-6766-201 (Verastem, Inc.)
Clinical Trial NCT04625270
ENGOT-ov60/NCRI (European Network for Gynaecological Oncological Trial groups)
GOG-3052 (The GOG Foundation)

Study Drugs or Compounds: VS-6766 and Defactinib (VS-6063)
Study Phase: Phase 2
Total Enrollment: Estimated at 100 patients

Study Short Title:
A Phase 2 Study of VS-6766 Alone and In Combination with Defactinib in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)

Sponsor:
Verastem Oncology

Three women having a laugh

People who participate in this trial must meet the following requirements:

  • You are a female, age 18 or older.

  • You have recurrent LGSOC.
  • You are willing to participate in a clinical trial.

Patients who enroll in the RAMP 201 trial:

  • Will attend study visits every two weeks.

  • Will take the study drug at home as an oral formulation.

  • Will not be charged to participate.

  • May withdraw from the trial at any time.

Check to learn if you pre-qualify

To see if you may be eligible, take our short pre-screener questionnaire.

Take the pre-screener